Your Shopping Cart Is Empty
| Report Code: A07133 | Dec 2021 | Pages: 261 | ||
| Tables: 126 | Charts: 49 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Cancer Supportive Care Drugs Market
Request Now !Global cancer supportive care drugs market was valued at $19,633.7 million in 2020 and is projected to reach $24,407.6 million by 2030 registering a CAGR of 2.2% from 2021 to 2030.cancer supportive care products refer to drugs or products primarily used for the treatment of adverse effects associated with cancer therapy, as well as to treat signs and symptoms of cancer, such as low blood counts, hair loss, vomiting, and nausea, among others. It is also sometimes used to reduce the side effects of cancer treatment by protecting certain cells or organs.
Growth in prevalence of cancer and adverse effects associated with the use cancer drugs, as well as surge in global geriatric population are some factors that drive the cancer supportive care drugs market. In addition, rise in uptake of biosimilars, and increase in government expenditure on healthcare, further boost the growth of the cancer supportive care drugs market. However, increase in advancements in targeted therapy drugs that have lesser side effects are discovered and preferred by the patients and doctors which is directly affecting the growth of the cancer supportive care drugs, may hamper the growth of the market. In addition, stringent regulatory process for biosimilar approval, also hinder the growth of the market. On the contrary, increase in R&D and number of pipeline cancer supportive care drugs, high growth potential in untapped emerging economies creates an opportunity for the manufacturers to tap and capitalize on the market.
The outbreak of COVID-19 has disrupted workflows in the healthcare sector around the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of healthcare. The COVID-19 pandemic has disrupted virtually each aspect of healthcare provision including cancer care. The impact of this pandemic on the cancer supportive care drugs market will provide learnings to pharmaceutical companies across other therapy areas both in the short and the long term. Moreover, outbreak of Coronavirus disease (COVID-19) has acted as a significant restraint on the cancer supportive care drugs market in 2020 as supply chains were disrupted due to restrictions on trade of pharmaceutical ingredients and products across countries. In addition, COVID 19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty in breathing. In its disruption to clinical trials and drug supply to patients, the COVID-19 pandemic has impacted the most crucial areas of the cancer supportive care drugs market. Pandemic has directly affected the supply of cancer supportive care drugs to cancer patients; not only is it difficult to administer chemotherapy and certain other treatments outside of a clinic, but the spread of coronavirus has reduced patients’ willingness and ability to access not just treatments, but trials for new medicines.
The global cancer supportive care drugs is segmented on the basis of type, application, distribution channel, and region to provide a detailed assessment of the market. By type, it is segmented into erythropoiesis-stimulating agents (ESA), granulocyte colony-stimulating factors (G-CSFs), antiemetics, bisphosphonates, opioids, NSAIDs (Non-Steroidal auto inflammatory drugs), and others. By application, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, stomach cancer, and others. Based on distribution channel, it is categorized into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Based on type, the market is segmented into erythropoiesis-stimulating agents (ESA), granulocyte colony-stimulating factors (G-CSFs), antiemetics, bisphosphonates, opioids, NSAIDs (Non-Steroidal auto inflammatory drugs), and others. The granulocyte colony-stimulating factors (G-CSFs) segment dominated the global market in 2020 and is expected to remain dominant throughout the forecast period owing to factors such as rising demand of granulocyte colony-stimulating factors (G-CSFs) for treatment of chemotherapy induced neutropenia.
Based on application, it is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, stomach cancer, and others. The breast segment dominated the global market in 2020 and is anticipated to continue this trend during the forecast period. This is attributed to rapidly increasing prevalence of breast cancer worldwide.
Based on distribution channel, it is classified into hospital pharmacies, drug stores and retail pharmacies, and online providers. The drug stores and retail pharmacies held the largest market share in 2020 and is expected to remain dominant throughout the forecast period owing to rising number of drug stores and retail pharmacies which provides both branded and generic cancer supportive care drugs coupled with discount and other benefits.
Asia-Pacific is the most lucrative region for cancer supportive care drugs, owing to presence of large patient population suffering from cancer and improvement in healthcare infrastructure in Asia-Pacific present potential opportunities for the key players operating in the cancer supportive care drugs market. Furthermore, as per WHO (2020), 95,03,710 new cancer cases were recorded in Asia-Pacific.
Furthermore, rise in disposable income in different countries of the region and surge in healthcare expenditure have led to increase in demand for cancer drugs, thereby boosting the market growth. Majority of market players have focused on expanding their foothold in Asia-Pacific by adopting strategies, such as merger, acquisition, and expansion to exploit the untapped opportunities in this region.
The key market players profiled in the report include Amgen Inc., Baxter International Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc (GSK) (Tesaro), Helsinn Healthcare, Heron Therapeutics, Johnson & Johnson (Janssen Global Services, LLC,), Merck KGAA, Novartis International AG (Sandoz), and Teva Pharmaceuticals.
Key Benefits For Stakeholders
Cancer Supportive Care Drugs Market Report Highlights
| Aspects | Details |
|---|---|
| By Type |
|
| By Application |
|
| By Distribution Channel |
|
| By Region |
|
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Rise in prevalence of cancer and adverse effects associated with
use of cancer drugs
3.5.1.2.Surge in global geriatric population
3.5.1.3.Rise in uptake of biosimilars
3.5.1.4.Increase in government expenditure on healthcare
3.5.2.Restraints
3.5.2.1.Advancements in targeted therapy drugs
3.5.2.2.Stringent regulatory process for biosimilar approval
3.5.3.Opportunities
3.5.3.1.Increase in R&D and number of pipeline cancer supportive care drugs
3.5.3.2.High growth potential in untapped emerging economies60
3.5.4.Impact analysis
3.6.COVID-19 Impact analysis on the cancer supportive care drugs
CHAPTER 4:CANCER SUPPORTIVE CARE DRUGS, BY TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.ESAs (Erythropoiesis stimulating agent)
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.G-CSFs (Granulocyte colony-stimulating factors)
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Antiemetics
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
4.5.Bisphosphonates
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country
4.6.Opioids
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast
4.6.3.Market analysis, by country
4.7.NSAIDs (Non-Steroidal auto inflammatory drugs)
4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast
4.7.3.Market analysis, by country
4.8.Others
4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast
4.8.3.Market analysis, by country
CHAPTER 5:CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Breast Cancer
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Lung Cancer
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Colorectal
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Prostate
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Liver Cancer
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
5.7.Stomach
5.7.1.Market size and forecast, by region
5.7.2.Market analysis, by country
5.8.Others
5.8.1.Market size and forecast, by region
5.8.2.Market analysis, by country
CHAPTER 6:CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospital Pharmacies
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Drug Stores and Retail Pharmacies
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.4.Online Providers
6.4.1.Market size and forecast
6.4.2.Market analysis, by country
CHAPTER 7:CANCER SUPPORTIVE CARE DRUGS, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country124
7.2.2.1.U.S.
7.2.2.1.1.U.S. cancer supportive care drugs, by type
7.2.2.1.2.U.S. cancer supportive care drugs, by application
7.2.2.1.3.U.S. cancer supportive care drugs, by distribution channel
7.2.2.2.Canada
7.2.2.2.1.Canada cancer supportive care drugs, by type
7.2.2.2.2.Canada cancer supportive care drugs, by application
7.2.2.2.3.Canada cancer supportive care drugs, by distribution channel
7.2.2.3.Mexico
7.2.2.3.1.Mexico cancer supportive care drugs, by type
7.2.2.3.2.Mexico cancer supportive care drugs, by application
7.2.2.3.3.Mexico cancer supportive care drugs, by distribution channel
7.2.3.North America market size and forecast, by type
7.2.4.North America market size and forecast, by application
7.2.5.North America market size and forecast, by distribution channel
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country141
7.3.2.1.Germany
7.3.2.1.1.Germany cancer supportive care drugs, by type
7.3.2.1.2.Germany cancer supportive care drugs, by application
7.3.2.1.3.Germany cancer supportive care drugs, by distribution channel
7.3.2.2.France
7.3.2.2.1.France cancer supportive care drugs, by type
7.3.2.2.2.France cancer supportive care drugs, by application
7.3.2.2.3.France cancer supportive care drugs, by distribution channel
7.3.2.3.UK
7.3.2.3.1.UK cancer supportive care drugs, by type
7.3.2.3.2.UK cancer supportive care drugs, by application
7.3.2.3.3.UK cancer supportive care drugs, by distribution channel
7.3.2.4.Italy
7.3.2.4.1.Italy cancer supportive care drugs, by type
7.3.2.4.2.Italy cancer supportive care drugs, by application
7.3.2.4.3.Italy cancer supportive care drugs, by distribution channel
7.3.2.5.Spain
7.3.2.5.1.Spain cancer supportive care drugs, by type
7.3.2.5.2.Spain cancer supportive care drugs, by application
7.3.2.5.3.Spain cancer supportive care drugs, by distribution
channel
7.3.2.6.Rest of Europe
7.3.2.6.1.Rest of Europe cancer supportive care drugs, by type
7.3.2.6.2.Rest of Europe cancer supportive care drugs,
by application
7.3.2.6.3.Rest of Europe cancer supportive care drugs,
by distribution channel
7.3.3.Europe market size and forecast, by type
7.3.4.Europe market size and forecast, by application
7.3.5.Europe market size and forecast, by distribution channel
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country
7.4.2.1.Japan
7.4.2.1.1.Japan cancer supportive care drugs, by type
7.4.2.1.2.Japan cancer supportive care drugs, by application
7.4.2.1.3.Japan cancer supportive care drugs, by distribution
channel
7.4.2.2.China
7.4.2.2.1.China cancer supportive care drugs, by type
7.4.2.2.2.China cancer supportive care drugs, by application
7.4.2.2.3.China cancer supportive care drugs, by distribution
channel
7.4.2.3.Australia
7.4.2.3.1.Australia cancer supportive care drugs, by type
7.4.2.3.2.Australia cancer supportive care drugs, by application
7.4.2.3.3.Australia cancer supportive care drugs, by distribution channel
7.4.2.4.India
7.4.2.4.1.India cancer supportive care drugs, by type
7.4.2.4.2.India cancer supportive care drugs, by application
7.4.2.4.3.India cancer supportive care drugs, by distribution
channel
7.4.2.5.South Korea
7.4.2.5.1.South Korea cancer supportive care drugs, by Type
7.4.2.5.2.South Korea cancer supportive care drugs, by application
7.4.2.5.3.South Korea cancer supportive care drugs, by
distribution channel
7.4.2.6.Rest of Asia-Pacific
7.4.2.6.1.Rest of Asia-Pacific cancer supportive care drugs, by type
7.4.2.6.2.Rest of Asia-Pacific cancer supportive care drugs, by application
7.4.2.6.3.Rest of Asia-Pacific cancer supportive care drugs, by distribution channel
7.4.3.Asia-Pacific market size and forecast, by type
7.4.4.Asia-Pacific market size and forecast, by application
7.4.5.Asia-Pacific market size and forecast, by distribution channel
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country201
7.5.2.1.Brazil
7.5.2.1.1.Brazil cancer supportive care drugs, by type
7.5.2.1.2.Brazil cancer supportive care drugs, by application
7.5.2.1.3.Brazil cancer supportive care drugs, by distribution
channel
7.5.2.2.Saudi Arabia
7.5.2.2.1.Saudi Arabia cancer supportive care drugs, by type
7.5.2.2.2.Saudi Arabia cancer supportive care drugs, by application
7.5.2.2.3.Saudi Arabia cancer supportive care drugs, by
distribution channel
7.5.2.3.South Africa
7.5.2.3.1.South Africa cancer supportive care drugs, by type
7.5.2.3.2.South Africa cancer supportive care drugs, by application
7.5.2.3.3.South Africa cancer supportive care drugs, by
distribution channel
7.5.2.4.Rest of LAMEA
7.5.2.4.1.Rest of LAMEA cancer supportive care drugs, by type
7.5.2.4.2.Rest of LAMEA cancer supportive care drugs, by
application
7.5.2.4.3.Rest of LAMEA cancer supportive care drugs, by
distribution channel
7.5.3.LAMEA market size and forecast, by type
7.5.4.LAMEA market size and forecast, by application
7.5.5.LAMEA market size and forecast, by distribution channel
CHAPTER 8:COMPANY PROFILES
8.1.AMGEN INC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.BAXTER INTERNATIONAL INC.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product Portfolio
8.2.5.Business performance
8.3.F. HOFFMANN-LA ROCHE LTD.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance.
8.4.GLAXOSMITHKLINE PLC (GSK) (TESASRO)
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance.
8.5.HELSINN HEALTHCARE
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.6.HERON THERAPEUTICS
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC,)
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.8.MERCK KGAA
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product Portfolio
8.8.5.Business performance
8.9.NOVARTIS INTERNATIONAL AG (SANDOZ)
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.10.TEVA PHARMACEUTICALS
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
LIST OF TABLES
TABLE 01.GLOBAL CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 02.CANCER SUPPORTIVE CARE DRUGS FOR ERYTHROPOIESIS STIMULATING AGENT (ESAS), BY REGION,
2020–2030 ($MILLION)
TABLE 03.CANCER SUPPORTIVE CARE DRUGS FOR GRANULOCYTE COLONY-STIMULATING FACTORS (G-CSFS),
BY REGION, 2020–2030 ($MILLION)
TABLE 04.CANCER SUPPORTIVE CARE DRUGS FOR ANTIEMETICS, BY REGION, 2020–2030 ($MILLION)
TABLE 05.CANCER SUPPORTIVE CARE DRUGS FOR BISPHOSPHONATES, BY REGION, 2020–2030 ($MILLION)
TABLE 06.CANCER SUPPORTIVE CARE DRUGS FOR OPIOIDS, BY REGION, 2020–2030 ($MILLION)
TABLE 07.CANCER SUPPORTIVE CARE DRUGS FOR NSAIDS (NON-STEROIDAL AUTO INFLAMMATORY DRUGS),
BY REGION, 2020–2030 ($MILLION)
TABLE 08.CANCER SUPPORTIVE CARE DRUGS FOR OTHERS, BY REGION, 2020–2030 ($MILLION)
TABLE 09.GLOBAL CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 10.CANCER SUPPORTIVE CARE DRUGS FOR BREAST, BY REGION, 2020–2030 ($MILLION)
TABLE 11.CANCER SUPPORTIVE CARE DRUGS FOR LUNG, BY REGION, 2020–2030 ($MILLION)
TABLE 12.CANCER SUPPORTIVE CARE DRUGS FOR COLORECTAL, BY REGION, 2020–2030 ($MILLION)
TABLE 13.CANCER SUPPORTIVE CARE DRUGS FOR PROSTATE, BY REGION, 2020–2030 ($MILLION)
TABLE 14.CANCER SUPPORTIVE CARE DRUGS FOR LIVER, BY REGION, 2020–2030 ($MILLION)
TABLE 15.CANCER SUPPORTIVE CARE DRUGS FOR STOMACH, BY REGION, 2020–2030 ($MILLION)
TABLE 16.CANCER SUPPORTIVE CARE DRUGS FOR OTHERS, BY REGION, 2020–2030 ($MILLION)
TABLE 17.GLOBAL CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 18.CANCER SUPPORTIVE CARE DRUGS FOR HOSPITAL PHARMACIES, BY REGION, 2020–2030 ($MILLION)
TABLE 19.CANCER SUPPORTIVE CARE DRUGS FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION,
2020–2030 ($MILLION)
TABLE 20.CANCER SUPPORTIVE CARE DRUGS FOR ONLINE PROVIDERS, BY REGION, 2020–2030 ($MILLION)
TABLE 21.CANCER SUPPORTIVE CARE DRUGS, BY REGION, 2020–2030 ($MILLION)
TABLE 22.NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 23.U.S. CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 24.U.S. CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 25.U.S. CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 26.CANADA CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 27.CANADA CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 28.CANADA CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 29.MEXICO CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 30.MEXICO CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 31.MEXICO CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 32.NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 33.NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 34.NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 35.EUROPE CANCER SUPPORTIVE CARE DRUGS, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 36.GERMANY CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 37.GERMANY CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 38.GERMANY CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 39.FRANCE CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 40.FRANCE CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 41.FRANCE CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 42.UK CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 43.UK CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 44.UK CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 45.ITALY CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 46.ITALY CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 47.ITALY CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 48.SPAIN CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 49.SPAIN CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 50.SPAIN CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 51.REST OF EUROPE CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 52.REST OF EUROPE CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 53.REST OF EUROPE CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 54.EUROPE CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 55.EUROPE CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 56.EUROPE CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 57.ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 58.JAPAN CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 59.JAPAN CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 60.JAPAN CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 61.CHINA CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 62.CHINA CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 63.CHINA CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 64.AUSTRALIA CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 65.AUSTRALIA CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 66.AUSTRALIA CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 67.INDIA CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 68.INDIA CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 69.INDIA CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 70.SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 71.SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 72.SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030
($MILLION)
TABLE 73.REST OF ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 74.REST OF ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 75.REST OF ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 76.ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 77.ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 78.ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030
($MILLION)
TABLE 79.LAMEA CANCER SUPPORTIVE CARE DRUGS, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 80.BRAZIL CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 81.BRAZIL CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 82.BRAZIL CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 83.SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 84.SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 85.SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030
($MILLION)
TABLE 86.SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 87.SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 88.SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL 2020–2030
($MILLION)
TABLE 89.REST OF LAMEA CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 90.REST OF LAMEA CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 91.REST OF LAMEA CANCER SUPPORTIVE CARE DRUGS, DISTRIBUTION CHANNEL, 2020–2030
($MILLION)
TABLE 92.LAMEA CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020–2030 ($MILLION)
TABLE 93.LAMEA CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 94.LAMEA CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 95.AMGEN: COMPANY SNAPSHOT
TABLE 96.AMGEN: OPERATING SEGMENT
TABLE 97.AMGEN: PRODUCT PORTFOLIO
TABLE 98.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 99.BAXTER: COMPANY SNAPSHOT
TABLE 100.BAXTER: BUSINESS UNITS
TABLE 101.BAXTER: PRODUCT PORTFOLIO
TABLE 102.ROCHE: COMPANY SNAPSHOT
TABLE 103.ROCHE: OPERATING SEGMENTS
TABLE 104.ROCHE: PRODUCT PORTFOLIO
TABLE 105.GSK: COMPANY SNAPSHOT
TABLE 106.GSK: OPERATING SEGMENTS
TABLE 107.GSK: PRODUCT PORTFOLIO
TABLE 108.HELSINN: COMPANY SNAPSHOT
TABLE 109.HELSINN: OPERATING SEGMENTS
TABLE 110.HELSINN: PRODUCT PORTFOLIO
TABLE 111.HERON THERAPEUTICS: COMPANY SNAPSHOT
TABLE 112.HERON THERAPEUTICS: OPERATING SEGMENT
TABLE 113.HERON THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 114.HERON THERAPEUTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 115.J&J: COMPANY SNAPSHOT
TABLE 116.J&J: OPERATING SEGMENTS
TABLE 117.J&J: PRODUCT TYPE PORTFOLIO
TABLE 118.MERCK: COMPANY SNAPSHOT
TABLE 119.MERCK: OPERATING SEGMENTS
TABLE 120.MERCK: PRODUCT PORTFOLIO
TABLE 121.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 122.NOVARTIS: OPERATING SEGMENTS
TABLE 123.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 124.TEVA: COMPANY SNAPSHOT
TABLE 125.TEVA: OPERATING SEGMENTS
TABLE 126.TEVA: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.CANCER SUPPORTIVE CARE DRUGS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 04.MODERATE BARGAINING POWER OF BUYERS
FIGURE 05.MODERATE THREAT OF SUBSTITUTES
FIGURE 06.MODERATE THREAT OF NEW ENTRANTS
FIGURE 07.HIGH INTENSITY OF RIVALRY
FIGURE 08.TOP PLAYER POSITIONING, 2020
FIGURE 09.IMPACT ANALYSIS
FIGURE 10.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR ESAS (ERYTHROPOIESIS
STIMULATING AGENT), BY COUNTRY, 2020 & 2030 (%)
FIGURE 11.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR G-CSFS (GRANULOCYTE
COLONY-STIMULATING FACTORS), BY COUNTRY, 2020 & 2030 (%)
FIGURE 12.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR ANTIEMETICS, BY COUNTRY,
2020 & 2030 (%)
FIGURE 13.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR BISPHOSPHONATES,
BY COUNTRY, 2020 & 2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR OPIOIDS, BY COUNTRY,
2020 & 2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR NSAIDS (NON-STEROIDAL
AUTO INFLAMMATORY DRUGS), BY COUNTRY, 2020 & 2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR OTHERS, BY COUNTRY,
2020 & 2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS CANCER SUPPORTIVE CARE DRUGS FOR BREAST, BY COUNTRY,
2020 & 2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR LUNG, BY COUNTRY,
2020 & 2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR COLORECTAL, BY COUNTRY,
2020 & 2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR PROSTATE, BY COUNTRY,
2020 & 2030 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR SKIN, BY COUNTRY,
2020 & 2030 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR STOMACH, BY COUNTRY,
2020 & 2030 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR OTHERS, BY COUNTRY,
2020 & 2030 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR HOSPITAL PHARMACIES,
BY COUNTRY, 2020 & 2030 (%)
FIGURE 25.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 26.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR ONLINE PROVIDERS,
BY COUNTRY, 2020 & 2030 (%)
FIGURE 27.AMGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 28.AMGEN: REVENUE SHARE BY REGION, 2019(%)
FIGURE 29.BAXTER: NET SALES, 2018–2020 ($MILLION)
FIGURE 30.BAXTER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31.BAXTER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 32.ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 33.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34.ROCHE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 35.GSK: NET SALES, 2018–2020 ($MILLION)
FIGURE 36.GSK: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 37.GSK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 38.HERON THERAPEUTICS: NET SALES, 2018–2020 ($MILLION)
FIGURE 39.J&J: REVENUE, 2018–2020 ($MILLION)
FIGURE 40.J&J: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 41.J&J: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 42.MERCK: NET SALES, 2018-2020 ($MILLION)
FIGURE 43.MERCK: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 44.MERCK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 45.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 46.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 47.NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 48.TEVA.: REVENUE, 2018–2020 ($MILLION)
FIGURE 49.TEVA: REVENUE SHARE BY REGION, 2020 (%)
Cancer supportive care drugs are also called protective drugs which are used to alleviate the side effects of cancer therapy. Supportive drugs are not used to treat cancer. During chemotherapy there are number of complications that can arise because of side effects of chemotherapy such as anemia, neutropenia, diarrhea, mucositis, extreme pain, nausea and vomiting, inflammation of different body parts, and many more. Thus to treat such conditions supportive care drugs are an integral component of all oncological treatments.
Rise in prevalence of cancer and adverse effects associated with the use cancer drugs, surge in global geriatric population, rise in uptake of biosimilars, and increase in government expenditure on healthcare are some factors which boost growth of the market. Furthermore, increase in R&D and number of pipeline cancer supportive care drugs, and high growth potential in untapped emerging economies are expected to create a lucrative opportunity for market growth. However, increase in advancements in targeted therapy drugs, and stringent regulatory process for biosimilar approval are some factors which are expected to hinder growth of the market.
A. The total market value of cancer supportive care drugs market is $19,633.7 million in 2020.
A. The forcast period for cancer supportive care drugs market is 2021 to 2030
A. The market value of cancer supportive care drugs market in 2021 is $24,407.64 million.
A. The base year is 2020 in cancer supportive care drugs market
A. Top companies such as Novartis AG, Johnson & Johnson, Amgen Inc., Baxter International Inc., Fagron Group BV and Teva Pharmaceuticals Industries Ltd. held a high market position in 2020.
A. Based on type, the G-CSFs (Granulocyte colony-stimulating factors) segment accounted for the largest share of the cancer supportive care drugs market in 2020. The large share of this segment can be attributed to the increasing prevalence of chemotherpay induced neutropenia (CIN) that is reduction of neutriphils in the blood due to toxicity caused by the administration of anticancer drugs.
A. Growth in prevalence of all types cancer worldwide and rise in demand of biosimilars for treatment of cancer are some factors which drive growth of the cancer supportive care drugs market. In addition, increase in surge in global geriatric population and increasing healthcare expenditure by government will further boost growth of the cancer supportive care drugs market.
A. North America is projected to account for a major share of 40.3% the global cancer supportive care drugs market during the forecast period. The market in the region is anticipated to grow in the future, owing to rising pipeline drug development in the U.S., large patient population suffering from cancer. Moreover, presence of major key players such as Amgen, Baxter International, Johnson & Johnson, and Heron Pharmaceuticals in the region and rising number of product approvals are propelling market growth in North America.
A. Cancer supportive care drugs are used to lessen the harmful side effects of cancer treatment by protecting certain cells or organs. Supportive drugs are not used to treat cancer. Supportive drugs are also called protective drugs.
A. The cancer supportive care drugs market products are used for the treatment of patients who are suffering from adverse side effects of chemotherapy. The adverse side effcets of chemotherapy includes anemia, neutropenia, nausea, vomiting, diarrhea, weakness, infections, fatigue and many more.
Start reading instantly.
This Report and over 67,132+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report